Humanetics Executive and Leadership Team

Amit Singhi, the Chief Financial Officer at Humanetics, directs all financial operations and strategic fiscal planning. Overseeing capital allocation and investment strategies, Singhi ensures robust financial health to support the company's clinical-stage drug development pipeline. This leadership role involves managing budgets, forecasting financial performance, and securing funding necessary for the accelerated discovery and commercialization of proprietary drugs. By optimizing resource deployment, Amit Singhi directly supports the company's focus on medical countermeasures and radiation modulators for oncology and inflammatory lung diseases. Singhi's financial acumen drives the efficient execution of research and development initiatives, positioning Humanetics for sustained growth and market impact in areas with urgent, unmet medical needs.

Karsten Newbury, the President, Humanetics Digital at Humanetics, spearheads the strategic direction and operational execution of the company's digital ventures. Newbury drives the expansion of digital solutions designed to accelerate drug discovery and development, ensuring alignment with the company's core mission. This leadership position involves fostering innovation within the digital division, enhancing market reach, and optimizing the commercialization pathways for proprietary drugs. By focusing on advanced digital technologies, Karsten Newbury directly supports Humanetics' commitment to addressing urgent, unmet medical needs, particularly in the development of medical countermeasures and radiation modulators for oncology and inflammatory lung diseases. Newbury's leadership ensures that Humanetics remains at the forefront of digital innovation within the pharmaceutical sector.

Barney Loehnis, the President, Humanetics Sensors at Humanetics, directs the strategic growth and operational excellence of the company's sensor division. Loehnis oversees the innovation and deployment of advanced sensor technologies that enhance the company's capabilities in drug development and medical countermeasures. This executive role involves driving market penetration and ensuring the technological superiority of Humanetics' sensor products, directly supporting the company's focus on oncology and inflammatory lung diseases. By leading the sensor division, Barney Loehnis contributes significantly to the accelerated discovery and commercialization of proprietary drugs, ensuring that Humanetics maintains a competitive edge in addressing urgent, unmet medical needs. Loehnis's vision guides the development of next-generation sensing solutions.

Barnaby Loehnis, the President, Humanetics Sensors at Humanetics, leads the strategic expansion and technological advancement of the company's sensor technologies. Loehnis focuses on developing and integrating cutting-edge sensor solutions that bolster the company's drug discovery and development efforts, particularly for medical countermeasures. This leadership role involves driving operational efficiency within the sensor division and ensuring product quality that aligns with Humanetics' commitment to addressing urgent, unmet medical needs in oncology and inflammatory lung diseases. By championing innovation in sensor technology, Barnaby Loehnis plays a crucial part in the accelerated commercialization of proprietary drugs. Loehnis's strategic oversight enhances the company's research capabilities and market position.

Sandra Coleman, the Chief Technology Officer, Humanetics Digital at Humanetics, architects the technological vision and strategy for the company's digital initiatives. Overseeing the development and implementation of innovative digital platforms, Coleman ensures seamless integration of technology across all business functions, particularly supporting the accelerated discovery and development of proprietary drugs. This critical role involves driving technological advancements that enhance operational efficiency and data analytics capabilities, directly impacting the company's focus on medical countermeasures and radiation modulators. By leading the digital transformation efforts, Sandra Coleman ensures that Humanetics leverages cutting-edge technology to address urgent, unmet medical needs in oncology and inflammatory lung diseases, solidifying the company's position as a leader in pharmaceutical innovation.